Source: Eur Respir J 2002; 20: 990-995
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Antunes G., Evans S.A., Lordan J.L., Frew A.J.. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002; 20: 990-995

Member's Comments

No comment yet.

Related content which might interest you: Systemic cytokine response in patients with community-acquired pneumonia Source: Eur Respir J 2011; 37: 1431-1438 Year: 2011 D-dimer elevation is associated with severity of community-acquired pneumonia according to CURB-65 and PSI Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Local and systemic cytokine profiles in patients with non-severe and severe community-acquired pneumonia Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012 The clinical significance of serum and bronchoalveoalr lavage inflammatory cytokine in patients with acute respiratory failure due to severe community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 347s Year: 2006 COPD is associated with increased mortality in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: 346-351 Year: 2006 Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression Source: Eur Respir J 2012; 40: 1201-1210 Year: 2012 Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Factors associated with inflammatory cytokine patterns in community-acquired pneumonia Source: Eur Respir J 2011; 37: 393 Year: 2011 The impact of patients‘ age and concomitant diseases on community-acquired pneumonia outcome Source: Eur Respir J 2007; 30: Suppl. 51, 675s Year: 2007 Management-based risk prediction in community-acquired pneumonia by scores and biomarkers Source: Eur Respir J 2013; 41: 974-984 Year: 2013 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia Source: Eur Respir J 2013; 41: 1378-1385 Year: 2013 Comparison of inflammatory response biomarkers to predict complications in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia Source: Eur Respir J 2007; 30: 517-524 Year: 2007 Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008 Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients Source: Eur Respir J 2012; 39: 855-861 Year: 2012 Biomarkers and severity in community-acquired pneumonia (CAP) Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 Neutrophil extracellular traps levels are associated to severity and complications in community-acquired pneumonia Source: Virtual Congress 2020 – Biomarkers and characterisation of immune response in respiratory infection Year: 2020 Clinical pulmonary infection score (CPIS) and inflammatory response in patients with new pulmonary infiltrates and suspected ventilator acquired pneumonia (VAP) Source: Annual Congress 2005 - Diagnosis and prognosis of ventilator associated pneumonia: the clinical track Year: 2005